1. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. (1st February 2022) Authors: Mills, Anthony; Richmond, Gary J.; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Margolis, David A.; Sutton, Kenneth C.; Wilches, Viviana; Hatch, Sarah; Roberts, Jeremy; McCoig, Cynthia; Garris, Cindy; Vandermeulen, Kati; Spreen, William R. Journal: AIDS Issue: Volume 36:Number 2(2022) Page Start: 195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. (1st February 2022) Authors: Mills, Anthony; Richmond, Gary J.; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Margolis, David A.; Sutton, Kenneth C.; Wilches, Viviana; Hatch, Sarah; Roberts, Jeremy; McCoig, Cynthia; Garris, Cindy; Vandermeulen, Kati; Spreen, William R. Journal: AIDS Issue: Volume 36:Number 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗